Immune-checkpoint blockade
Sitravatinib potentiates immune checkpoint blockade in refractory cancer models
... of immune checkpoint blockade, and a large portion of cancer patients remain refractory to this important new treatment modality ...to immune checkpoint blockade, especially ...
11
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
... with immune checkpoint inhibitors (blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and blockade of the programmed cell death-1 (PD-1) receptor) have shown promising ...on ...
7
Central nervous system toxicities of anti-cancer immune checkpoint blockade
... Thus, immune-related CNS toxicities following immune checkpoint blockade likely involve varied mechanisms including neuronal damage by T-cells, autoantibodies and/ or cytokine-mediated ...
7
CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade
... with immune checkpoint blockade (ICB) has now also demonstrated clear activity in approximately 15%–25% of patients with metastatic disease, often with impressive duration of response, leading the US ...
18
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
... ICB: Immune checkpoint blockade; IFN: Interferon; IL: Interleukin; IMiDs: Immunomodulatory drugs; irAE: Immune-related adverse events; JAK: Janus kinase; KO: Knock out; LAG-3: Lymphocyte ...
20
Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade
... Background: Antibodies against programmed death 1 (PD-1) receptor and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have transformed the systemic treatment of melanoma and many other cancers. Understanding the ...
5
Prospects for combining immune checkpoint blockade with PARP inhibition
... anti-cancer immune response tends to be ...signals. Immune checkpoint inhibitors block negative co-stimulatory signals such as programmed cell death-1 and cytotoxic T-lymphocyte-associated protein 4, ...
12
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
... cancers, immune checkpoint blockade inhibitors are a promising immunotherapeutic option in hematologic malignancies, and PD-1-PD-L1 axis blockers are the most investigated candidates to ...axis ...
15
Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
... immunological checkpoint blockades, CTLA-4: CD80/CD86 interactions and PD-1: PD-L1 interactions, are broadly used in anti-tumor im- ...commercial checkpoint drug approved by FDA for cancer immuno- therapy ...
6
Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series.
... Rechallenge immune checkpoint blockade with combination ipi + nivo may be efficacious, although there is potential for substantial toxicity. These cases demonstrate that toxicity is likely to recur ...
12
An unsuspected complication with immune checkpoint blockade: a case report
... irAEs have been described in almost every organ, includ- ing endocrine dysfunction. In a retrospective study con- ducted by Villa et al. [9], including patients who were treated with both anti-CTLA-4 (ipilimumab) and ...
5
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
... Our data have several implications for the clinical optimiza- tion of immune checkpoint blockade. Major B cell contribution to IRAEs may provide the opportunity to separate mechanisms of autoimmunity ...
7
Tumor Interferon Signaling Initiates And Sustains A Multigenic Resistance Program To Immune Checkpoint Blockade
... 2: Immune cells expressing PD-L1 mediate resistance to anti-CTLA4 and radiotherapy in relapse but not parental tumor lines ...to immune checkpoint blockade occurs in both mice and patients ...
117
The role of neoantigen in immune checkpoint blockade therapy
... Immune checkpoint inhibitor induces tumor rejection by activated host immune ...anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent ...
11
Smoldering myocarditis following immune checkpoint blockade
... with immune checkpoint blockade-induced myocarditis based upon an acute rise in serum cardiac troponin I beginning 2 weeks after the initial dose of ipilimumab/nivolumab consistent with the reported ...
6
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
... combined checkpoint blockade appears more favorable, although external cohorts should be interpreted with caution and the comparison may be subject to significant ...
9
C3d regulates immune checkpoint blockade and enhances antitumor immunity
... limits immune surveillance of cancer — and perhaps more ...effective immune surveillance of ...whether immune sur- veillance or immune suppression ...
13
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
... progression-free survival in patients with metastatic melanoma, however the combination therapy increases the risk of immune-related adverse events, in particular diarrhea/colitis, hepatitis, pruritus/rash and ...
7
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
... 4]. Immune-mediated endocrinopa- thies are among the most common ...reported immune-mediated endocrinopathies are hypophysitis and thyroid dysfunction while type 1 diabetes mellitus and adrenal ...
5
Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
... Assessment of enrichment of specific mutated genes with response (CR/PR versus PD/SD) was done with fisher’s exact test and the P values were controlled for false discovery rate (FDR). The association be- tween TET1 ...
13